Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Clinical trials sponsored by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., explained in plain language.
Pharmaceutical company, subsidiary of Huadong Medicine.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill HDM2006 tested in patients with advanced cancers Results expected Sep 2026 (estimated)
- New weekly shot aims to shed pounds in obesity trial Results expected Sep 2026 (estimated)
- New Drug's heart safety checked in healthy volunteers Results expected Sep 2026 (estimated)
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly Results expected Oct 2026 (estimated)
- New diabetes pill HDM1002 enters final testing phase Results expected Oct 2026 (estimated)
-
New psoriasis cream shows promise in major trial
Disease control CompletedThis phase 3 trial tests a new cream (MC2-01) containing two active ingredients for plaque psoriasis in Chinese adults. About 537 participants will use either the new cream, a standard gel, or a placebo cream for 8 weeks. The main goal is to see if the new cream clears skin bette…
Phase 3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New Weight-Loss injection HDM1005 tested in small early trial
Disease control CompletedThis early-phase trial tested a new drug called HDM1005 in 40 overweight or obese adults. Participants received either the drug or a placebo as a shot under the skin. The main goal was to check safety and how the body processes the drug, not yet to prove it works for weight loss.
Phase 1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New cream shows promise for clearing psoriasis in chinese patients
Disease control CompletedThis Phase 3 study tests a cream called roflumilast (Zoryve) for treating plaque psoriasis in Chinese patients aged 6 years and older. The cream is applied once daily to reduce skin plaques. Researchers will measure how many patients achieve clear or almost clear skin after 8 wee…
Phase 3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New weight loss shot shows promise in early human testing
Disease control CompletedThis early-stage study tested a single dose of an investigational drug called HDM1005 in 65 healthy adults who were overweight or had obesity. The main goal was to check if the injection is safe and how the body processes it. Researchers also looked at changes in weight and other…
Phase 1 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New eczema cream shows promise in phase 3 trial
Symptom relief CompletedThis phase 3 trial tested a once-daily cream called roflumilast (0.15%) in 354 people aged 6 and older with mild to moderate atopic dermatitis (eczema). Participants applied the cream or a placebo for 4 weeks. The main goal was to see if the cream could make skin clear or almost …
Phase 3 • Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 26, 2026 12:51 UTC